The DOI matches its Crossref record.
LBA1 Pembrolizumab in combination with xelox and bevacizumab in patients with microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC) and a high immune infiltrate: A proof of concept study - Preliminary results of FFCD 1703 POCHI trial
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the FFCD 1703-POCHI trial, preliminary results show a 10-month progression-free survival rate of almost 70% in patients with a high extent of tumorous leucocyte infiltration.
“Preliminary results from this trial show a 10-month PFS rate of almost 70% in the group of patients with a high extent of tumorous leucocyte infiltration.119”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Still being checked.
Cited by
Sorted by citations
Current and emerging concepts for systemic treatment of metastatic colorectal cancer
Steup, C., Kennel, K. B., Neurath, M. F., Fichtner-Feigl, S., & Greten, F. R. (2025) · Gut · doi:10.1136/gutjnl-2025-335412 · Cited by 39
Iglesias, M., Badia-Ramentol, J., Martínez‐Ciarpaglini, C., Linares, J., Tarazona, N., Mulet-Margalef, N., Tornero-Piñero, P., Sallent-Aragay, A., Recort-Bascuas, A., Gibert, J., et al. (2026) · Gut · doi:10.1136/gutjnl-2025-336804 · Cited by 3
Passardi, A., Sullo, F. G., Bittoni, A., Matteucci, L., Rosa, F. D., Bulgarelli, J., Tazzari, M., Petrini, M., Scarpi, E., Testoni, S., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-15371-7 · Cited by 2
Ree, A. H., Bousquet, P. A., Visnovska, T., Lüders, T., Geisler, B. P., Wang, S., Bordin, D. L., Nilsen, H. L., Hamre, H. M., Kersten, C., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03357-6
Hendlisz, A., Shaza, L., Grez, T. D., & Awada, A. H. (2026) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001248
Truntzer, C., Thibaudin, M., Bousquet, P. A., Peroz, M., Dérangère, V., Ilie, A., Rageot, D., Flatmark, K., Ree, A. H., Meltzer, S., et al. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2671491
Metadata
- Authors
- Tougeron, D., Emile, J. F., Bodere, A., Barbier, E., Bez, J., Dourthe, L. M., Perrier, H., Corbinais, S., Le Brun-Ly, V., Bideau, K., Chibaudel, B., Khemissa, F., Hartwig, J., Laly, M., Lievre, A., Toullec, C., Muller, M., Laurent-Puig, P., Lepage, C., & Taieb, J.
- Affiliations
- Centre Hospitalier Universitaire de Poitiers (FR)
- Hôpital Ambroise-Paré (FR)
- Fédération Francophone de Cancérologie Digestive (FR)
- Hôpital Saint Joseph (FR)
- Centre François Baclesse (FR)
- Centre Hospitalier de Cornouaille (FR)
- Fondation Cognacq-Jay (FR)
- Centre Hospitalier de Perpignan (FR)
- Infirmerie Protestante (FR)
- Centre Hospitalier Départemental Vendée (FR)
- Institut Sainte Catherine (FR)
- CHU Dijon Bourgogne (FR)
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2024-06
- Volume
- 35
- Pages
- S212
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4400151376
- Cited by
- 6
- References
- 0
- Citations by year
- 2026: 4 · 2025: 2
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- pembrolizumab, bevacizumab, metastatic colorectal cancer, microsatellite stable, proficient mismatch repair, tumor-infiltrating lymphocytes, immune checkpoint inhibitors, immune score, CD8+ T cells, CD3+ T cells, combination therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
